Abstract Library

#4555 Assessment of gastric mucosa conditions changes in patients with gastric neuroendocrine neoplasia type 1 during gastroprotective therapy

Introduction: Currently, the incidence of gastric neuroendocrine neoplasia (gNEN) has increased significantly. Most gNEN are developed on the background of chronic atrophic gastritis (about 90%). Despite this, the role of chronic atrophic gastritis treatment (gastroprotective therapy) in dynamic of gNEN remains unexplored.

Conference:

Presenting Author: Konyakhina A

Authors: Konyakhina A, Feidorov I, Salimgereeva D, Petrova A,

Keywords: gNEN, atrophic gastritis, OLGA, rebamipide,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4413 Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia (APSIN) – A multi-centre, prospective, randomised, controlled, phase III study

Introduction: Our multi-centre, prospective, open-label, two-arm parallel group, randomised, controlled, phase III study will address the efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia.

Conference:

Presenting Author: Eilsberger F

Authors: Eilsberger F, Luster M, Rau J, Avci H, Schade-Brittinger C,

Keywords: adjuvant therapy, neuroendocrine neoplasia, small intestine, peptide receptor radionuclide therapy, PRRT,